Grace Therapeutics, Inc. (GRCE NASDAQ) stock market data APIs
$3.1596
-0.01(-0.3%)
as of November 21, 2025
Try our APIs with
free plan!
Grace Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Prev. Close
3.1596
Open
3.1519
High
3.1605
Low
3.1128
52 wk Range
1.75-4.97
Market Cap
48 405 K
Shares Outstanding
14 129 K
EPS
-0.0841
Beta
0.598
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Grace Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Grace Therapeutics, Inc. data using free add-ons & libraries
Get Grace Therapeutics, Inc. Fundamental Data
Grace Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -12 497 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.344
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Grace Therapeutics, Inc. News
New
Grace Therapeutics GAAP EPS of -$0.06 beats by $0.14
* Grace Therapeutics press release [https://seekingalpha.com/pr/20306088-grace-therapeutics-announces-second-quarter-2026-financial-results-provides-business-update] (GRCE [https://seekingalpha.com/...
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference
PRINCETON, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, ...
Grace Therapeutics GAAP EPS of -$0.21 beats by $0.01
* Grace Therapeutics press release [https://seekingalpha.com/pr/20197491-grace-therapeutics-announces-first-quarter-2026-financial-results-provides-business-update] (NASDAQ:GRCE [https://seekingalph...
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update
Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
